HOME
ABOUT LIWA
MEDIA CENTRE
OUR RESEARCH AREAS
EMPLOYMENT
EDUCATION
LUNG HEALTH
Asthma Asthma Asthma
COPD COPD COPD
Bronchiectasis Bronchiectasis Bronchiectasis
Lung Fibrosis Lung Fibrosis Lung Fibrosis
Lung Transplantation Lung Transplantation Lung Transplantation
Lung Cancer Lung Cancer Lung Cancer
FACT SHEETS FACT SHEETS FACT SHEETS
Q & As Q & As Q & As
SUPPORT LIWA
CONTACT US
LINKS

PULMONARY FIBROSIS

What is Pulmonary Fibrosis?

Pulmonary fibrosis is an abnormal formation of fibre-like scar tissue in the alveoli (air sacs which take oxygen to the lungs and expel carbon dioxide) and interstitial tissue (the tissues between and surrounding the alveoli) of the lungs. It is a chronic lung disease associated with inflammation. Inhaling small particles can cause damage to the alveoli. Pulmonary fibrosis occurs when the alveoli gradually become replaced by fibrotic tissue. This leads to scarring, which makes the lung tissue thicker and causes an irreversible loss of the tissue’s ability to transfer oxygen into the bloodstream. Pulmonary fibrosis can be a mild, severe or even life-threatening disease. If the disease progresses the lung tissues eventually thicken and become stiff, leading to breathlessness and difficulty breathing.

Symptoms

  • Breathlessness, especially during exercise
  • Chronic dry cough
  • Shortness of breath
  • Chest discomfort
  • Fatigue and weakness
  • Loss of appetite
  • Rapid weight loss
  • Enlargement at end of fingertips so they take on a bulbous appearance, often referred to as “clubbing” (the condition may progress to the point where any exertion is impossible)

Causes

The causes of the condition “idiopathic (of unknown origin) pulmonary fibrosis” are not known. However there are over 140 causes or associations with pulmonary fibrosis. A reaction to a microscopic injury or irritation in the lung causing inflammation appears to be one of the causes of pulmonary fibrosis. Although doctors may claim that pulmonary fibrosis is due to a given disease, such as sarcoidosis, the specific causes of those particular diseases may also be unknown. In addition there is a growing body of evidence which points to a genetic predisposition. Families with a history of pulmonary fibrosis have been found to have a mutation in the SP-C protein. Although the exact cause of pulmonary fibrosis remains unknown, associations have been made with the following:
  • Exposure to cigarette smoke
  • Inhaled environmental pollutants
  • Occupational pollutants, including asbestos, ground stone, metal dust or mouldy hay
  • A number of diseases can cause pulmonary fibrosis
    • Sarcoidosis
    • Scleroderma
    • Rheumatoid Arthritis
    • Lupus
    • Tuberculosis
    • Systemic Lupus Erthematosis
    • Grain handler’s lung
    • Bagassosis
    • Detergent worker’s lung
    • Hermansky Pudlak Syndrome
  • Certain strong mediations
    • Nitiofurantoin [for urinary tract infections]
    • Amiodarone [for an irregular heart rate]
    • Bleomycin, cyclophosphamide and methotrexate [for fighting cancer]
  • Therapeutic radiation

Diagnosis

A number of different diagnostic techniques are used to diagnose pulmonary fibrosis. Indicators which may point towards a patient having pulmonary fibrosis include:

  • Chest x-rays
  • Pulmonary function tests – These tests reveal the efficiency of a patient’s breathing mechanism
  • Bronchoalveolar lavage – Cells in the lower respiratory tract are removed and examined
  • Injection with gallium 67 – Inflamed areas absorb gallium 67 which can later be seen on sensitized film
  • Lung biopsy – allows an examination of cells in and around the alveoli

Prognosis

The outcomes of pulmonary fibrosis differ for each individual. In many cases pulmonary fibrosis remains mild and takes a number of years to slowly progress. However, in other cases pulmonary fibrosis may be due to underlying diseases such as rheumatoid arthritis. These underlying diseases may progress and affect the pulmonary fibrosis itself. Pulmonary fibrosis tends to result in a slow progressive scarring of the lungs. Unfortunately some patients do not respond positively to therapy and their lungs will slowly deteriorate over a period of months or years until they are no longer able to function adequately. Alternatively other patients have a positive response to therapy. The duration and speed of the onset of pulmonary fibrosis differs on a case by case basis.

Treatment

If one of the known causes of pulmonary fibrosis exists then that underlying disease can be treated in order to limit the inflammation in the lungs. Limited inflammation will prevent the formation of scar tissue in the lungs and hopefully stop the progression of pulmonary fibrosis. However, due to the lack of standard diagnostic criteria, no effective treatments or a cure for pulmonary fibrosis currently exist.

Drugs known as corticosteroids are usually administered in order to try to stop the inflammation. It is best to give corticosteroid medications as early in the course of the disease as possible, as there appears to be a better chance of improvement. However treatment with corticosteroids has not proven to be effective in all cases. In addition corticosteroid medications have a number of side effects, meaning that the safety and benefit of using these medications must be continually reassessed by a doctor or physician.
Although much more research is required regarding drug therapy for pulmonary fibrosis, a number of supportive therapy programs exist to help patients adjust to symptoms of this condition. These include education and rehabilitation programs, which assist patients to breathe efficiently and to perform daily activities while keeping breathlessness to a minimum.

Supplemental oxygen can be administered in order to treat breathlessness and to improve a patient’s quality of life and exercise capacity. Removing the patient from the environment in which pollutants are being inhaled can also assist in limiting the progression of the disease. Chest infections require early treatment. Some patients may be considered for a single lung transplant. In addition, patients must quit smoking, as tobacco aggravates shortness of breath.

 
|
  Publications  
|
  Staff  
|
  Careers  
|
  Donations  
|
LIWA Online Donations
LIWA Members Area
Last updated 17 Nov 2006 15:57
Location:  http://www.liwa.uwa.edu.au/page/3986
Page Information | Printer Friendly Version